No Data
No Data
Express News | Jimin Medical: Projects related to the stem cell drug development pipeline are all in the pre-clinical stage
Express News | Jimin Medical: There have been no major changes in the company's main business and no major changes have occurred in the internal and external business environment
The concept of cellular immunotherapy fluctuated and declined. Jimin Medical and Nanhua Biotech fell to a standstill, Tailin Biotech fell by more than 8%, and Nanjing Xinbai and Sihuan Biotech followed suit.
The concept of cellular immunotherapy fluctuated and declined. Jimin Medical and Nanhua Biotech fell to a standstill, Tailin Biotech fell by more than 8%, and Nanjing Xinbai and Sihuan Biotech followed suit.
The medical device sector fluctuated and declined, and Jimin Medical fell to a standstill
The medical device sector fluctuated and declined. Jimin Medical fell to a standstill, Sano Healthcare fell by more than 4%, and Aipon Healthcare, Kangzhong Healthcare, and Weili Healthcare followed suit.
Express News | Jimin Medical: The company's current stem cell drug development pipeline related projects are in the pre-clinical stage
Chimin Health Management Co., Ltd. (SHSE:603222) Stock Rockets 31% As Investors Are Less Pessimistic Than Expected
Chimin Health Management Co., Ltd. (SHSE:603222) shares have continued their recent momentum with a 31% gain in the last month alone. Not all shareholders will be feeling jubilant, since the share
No Data